GEN Pharmaceuticals Secures Approval to Test New Parkinson's Treatment in Europe
Amsterdam, Monday, 16 March 2026.
Securing Dutch ethical approval, GEN Pharmaceuticals will launch a Phase II trial this April for a novel drug uniquely targeting cellular energy loss to combat Parkinson’s disease.
A Novel Approach to Cellular Energy in Neurodegeneration
On March 16, 2026, Türkiye-based specialty pharmaceutical company GEN Pharmaceuticals (GENIL.IS) announced it had received ethical clearance from the BEBO Foundation in the Netherlands to proceed with a Phase II Proof of Concept trial [1]. The trial centers on SUL-238, an experimental molecule licensed from the Dutch biotechnology firm Sulfateq B.V., which is based in Groningen [1]. Unlike traditional therapies that primarily manage dopaminergic symptoms, SUL-238 is specifically designed to support mitochondrial bioenergetics, addressing the underlying cellular energy deficits often observed in neurodegenerative conditions [1].
Stringent Parameters for the SHEPHERD Study
Officially titled the SHEPHERD study, the clinical trial is scheduled to begin patient enrollment in Groningen, the Netherlands, in April 2026 [1][2]. The study employs a randomized, double-blind, placebo-controlled design, ensuring that neither the participating patients nor the medical staff will know whether an individual is receiving the active SUL-238 coated tablets or a placebo until the four-week treatment period concludes [2]. This rigorous methodology is standard practice for late-stage clinical evaluations to prevent observation bias [GPT].
Advanced Spectroscopic Monitoring
A defining feature of the SHEPHERD trial is its reliance on advanced neuroimaging techniques to quantify the drug’s impact on brain energy metabolism. Before and during the study, participants will undergo phosphorus-31 magnetic resonance spectroscopy (31P-MRS) [1][2]. This specialized imaging modality allows researchers to non-invasively measure the concentrations of high-energy phosphates—specifically adenosine triphosphate (ATP), phosphocreatine, and inorganic phosphate—directly within the brain [1][2]. The scans will focus on key areas implicated in Parkinson’s disease, including the putamen, the substantia nigra, and the motor cortex [2].